Literature DB >> 10936198

Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors.

H Y Wang1, D H Lee, C B Davis, R P Shank.   

Abstract

We have recently reported evidence that a very high affinity interaction between the beta-amyloid peptide Abeta(1-42) and the alpha7 nicotinic acetylcholine receptor (alpha7nAChR) may be a precipitating event in the formation of amyloid plaques in Alzheimer's disease. In the present study, the kinetics for the binding of Abeta(1-42) to alpha7nAChR and alpha4beta2nAChR were determined using the subtype-selective nicotinic receptor ligands [(3)H]methyllycaconitine and [(3)H]cytisine. Synaptic membranes prepared from rat and guinea pig cerebral cortex and hippocampus were used as the source of receptors. Abeta(1-42) bound to the alpha7nAChR with exceptionally high affinity, as indicated by K(i) values of 4.1 and 5.0 pM for rat and guinea pig receptors, respectively. When compared with the alpha7nAChR, the affinity of Abeta(1-42) for the alpha4beta2nAChR was approximately 5,000-fold lower, as indicated by corresponding K(i) values of 30 and 23nM. The results of this study support the concept that an exceptionally high affinity interaction between Abeta(1-42) and alpha7nAChR could serve as a precipitating factor in the formation of amyloid plaques and thereby contribute to the selective degeneration of cholinergic neurons that originate in the basal forebrain and project to the cortex and hippocampus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10936198     DOI: 10.1046/j.1471-4159.2000.0751155.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  120 in total

1.  beta -Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons.

Authors:  Q Liu ; H Kawai; D K Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 2.  Membrane catalysis of peptide-receptor binding.

Authors:  David N Langelaan; Jan K Rainey
Journal:  Biochem Cell Biol       Date:  2010-04       Impact factor: 3.626

3.  Amyloid beta(1-42) peptide alters the gating of human and mouse alpha-bungarotoxin-sensitive nicotinic receptors.

Authors:  Francesca Grassi; Eleonora Palma; Raffaella Tonini; Mascia Amici; Marc Ballivet; Fabrizio Eusebi
Journal:  J Physiol       Date:  2003-01-17       Impact factor: 5.182

Review 4.  Nicotinic modulation of innate immune pathways via α7 nicotinic acetylcholine receptor.

Authors:  Wen-Yan Cui; Ming D Li
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-13       Impact factor: 4.147

Review 5.  Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors?

Authors:  M Zimmermann
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

6.  Distinct functional roles of Vps41-mediated neuroprotection in Alzheimer's and Parkinson's disease models of neurodegeneration.

Authors:  Edward F Griffin; Xiaohui Yan; Kim A Caldwell; Guy A Caldwell
Journal:  Hum Mol Genet       Date:  2018-12-15       Impact factor: 6.150

Review 7.  The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.

Authors:  Zi-Xuan Wang; Lan Tan; Jinyuan Liu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

Review 8.  Amyloid accomplices and enforcers.

Authors:  Andrei T Alexandrescu
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

9.  Subtype-specific actions of beta-amyloid peptides on recombinant human neuronal nicotinic acetylcholine receptors (alpha7, alpha4beta2, alpha3beta4) expressed in Xenopus laevis oocytes.

Authors:  Luanda Pym; Mark Kemp; Valérie Raymond-Delpech; Steven Buckingham; C A R Boyd; David Sattelle
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

10.  Pretreatment of chemically-synthesized Aβ42 affects its biological activity in yeast.

Authors:  Afsaneh Porzoor; Joanne M Caine; Ian G Macreadie
Journal:  Prion       Date:  2014       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.